Ebrahimpour, Afshin
Ahir, Manisha
Wang, Min
Jegga, Anil G.
Bonnen, Mark D.
Eissa, N. Tony
Montesi, Sydney B.
Raghu, Ganesh
Ghebre, Yohannes T.
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (T32HL007747-22)
National Institutes of Health (K01HL118683)
Cancer Prevention and Research Institutes of Texas (RP190497)
Baylor College of Medicine (2690000104)
Article History
Received: 27 July 2022
Accepted: 23 November 2022
First Online: 30 November 2022
Competing interests
: YTG is an inventor on patents, owned by Stanford University and Baylor College of Medicine, that protect the use of agents, including proton pump inhibitors (PPIs), for therapeutic use of new indications including IPF. MDB is an inventor on the patent owned by Baylor College of Medicine. AGJ serves as a member of Scientific Advisory Board of Gen1E Lifesciences, Palo Alto, CA, United States. SBM is supported by the NIH (K23HL15033). She has received funding through her institution from Merck, Boehringer Ingelheim and Pliant Therapeutics. She has received consulting fees from DevPro Biopharma, Gilead Sciences, and Roche, advisory board fees from APIE Therapeutics, and royalties from Wolters Kluwer. The other authors have no relevant conflict of interests to disclose.